Phase 2 Study of Azacitidine plus Pembrolizumab as Second-Line Treatment in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma [0.03%]
一项关于地西他滨联合派姆单抗作为二线治疗药物治疗局部晚期或转移性胰腺导管腺癌患者的II期研究
Rachael A Safyan,Ruth A White,Tamas A Gonda et al.
Rachael A Safyan et al.
Background: Epigenetic regulators represent a novel strategy to modulate the tumor immune microenvironment in pancreatic ductal adenocarcinoma (PDAC). In preclinical models, DNA hypomethylating agents enhance cytotoxic T-...
Accuracy of Patient, Care Partner, and Clinician Health Care Contact Day Recall [0.03%]
患者、护工及临床医师医疗就诊回忆准确性
Kendall Lin,Rick J Jansen,Manju George et al.
Kendall Lin et al.
Background: Contact days are increasingly used as a measure of time toxicity, but current measurement approaches (e.g., claims data) face limitations. To determine if participant recall of contact days could serve as a pr...
Identification of new prognostic molecular markers in glioblastoma: a single-center retrospective study [0.03%]
胶质母细胞瘤新的预后分子标志物的识别：单中心回顾性研究
Adèle Meola,Bertille Segier,Aurore Siegfried et al.
Adèle Meola et al.
Background: Glioblastoma (GBM) is the most common and aggressive primary CNS tumor in adults and carries a poor prognosis. Although molecular classification has advanced, patient outcomes remain variable. Next-generation ...
"Showing Some Care": Interest-Holders' Perspectives on Addressing Health-Related Social Conditions in Ovarian Cancer [0.03%]
“有所关怀”——卵巢癌患者利益相关者视角下关注健康相关的社会因素的影响
Anand R Habib,Sarah Pitafi,Elena Ratner et al.
Anand R Habib et al.
Background: Health-related social conditions (HRSCs) are modifiable factors affecting ovarian cancer outcomes. How best to manage HRSCs as part of ovarian cancer care remains unclear. We sought interest-holder perspective...
Planned Time Burden for Patients Participating in Phase 2 Cancer Trials [0.03%]
参与二期临床试验的癌症患者的预期时间负担
Charlotte Ouimet,Renata Iskander,Ryan Nipp et al.
Charlotte Ouimet et al.
Background: Participation in cancer trials requires a commitment of time and research burden from patients. Prior work has highlighted the time burden of clinic visits during phase 1 trial participation. We extended these...
Comparison of Six Cycles with Four Cycles of Chemotherapy and Atezolizumab in the First-Line Treatment of ES-SCLC; A Retrospective Multicenter Analysis [0.03%]
六周期与四周期化疗联合阿特朱单抗一线治疗广泛期小细胞肺癌：一项回顾性多中心分析
Halil Göksel Güzel,Derya Kıvrak Salim,Saadettin Kılıçkap et al.
Halil Göksel Güzel et al.
Aim: IMpower133 was designed with four cycles of chemoimmunotherapy with atezolizumab, unlike many other studies permitted six-cycle induction. This study aimed to compare the efficacy and safety of a four-cycle regimen w...
Linda Battistuzzi,Irene Giannubilo,Eva Blondeaux et al.
Linda Battistuzzi et al.
Background: Prognostic disclosure enables shared decision-making by keeping patients informed about their health and involved in treatment choices. Prognostic uncertainty is prominent in metastatic breast cancer (mBC) and...
Construction of a predictive model based on the risk of relapse after cytarabine consolidation therapy in AML patients [0.03%]
基于巩固治疗后复发风险的急性髓系白血病患者的预测模型构建
Min Ji,Yiping Hao,Wei Li et al.
Min Ji et al.
Background: Patients with acute myeloid leukemia (AML) are still at risk of relapse after consolidation therapy with cytarabine. Therefore, early identification and intervention of. ...
Benefit-risk balance of S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC) [0.03%]
辅助治疗II/III期直肠癌时S-1与UFT的利弊平衡（JFMC35-C1：ACTS-RC）
Jean-Christophe Chiem,Hatem Alharazin,Everardo D Saad et al.
Jean-Christophe Chiem et al.
Background: Given the superior relapse-free survival (RFS) and different safety profiles of 1 year of adjuvant S-1 or uracil/tegafur (UFT) for stage II/III rectal cancer, the benefit-risk of these two regimens was formall...